PROGRAMME OF LIVE SESSIONS: CET timing

The programme below will take place live. This time schedule corresponds to CEST timing. Click here to adapt the CET time schedule to your own time zone.

If you want to ask questions during the Panel Discussions and Round Tables or if you want to test your knowledge and vote during Interactive Case presentations and debates, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live.
To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting

ESH EUROPEAN SCHOOL OF HAEMATOLOGY

How to Diagnose and Treat
LYMPHOMA
November 6-8, 2020
Chairpersons: C. Buske, C. Thieblemont, A. Younes

Friday, November 6

10:00-10:10	**Welcome**	
10:10-12:05	**SESSION I – Hodgkin's Disease** **Chairs: Andreas Engert (Cologne) and Camille Laurent (Toulouse)**	
10:10-10:15	Introduction	
10:15-10:35	Diagnostics The boundaries of Hodgkin Lymphoma	Stefano Pileri (Milan)
10:35-10:55	First line Treatment Early stages	Marc André (Namur, Yvoir)
10:55-11:15	First line Treatment Intermediate/Advanced stages	Andreas Engert (Cologne)
11:15-11:35	Relapsed Disease	Pier Luigi Zinzani (Bologna)
11:35-11:40	*Refractory/relapsed hodgkin lymphoma: the profile of patients referred to autologous stem cell transplantation*	*Maria Eduarda Couto (Porto)*
11:40-12:05	*Discussion Q & A*	

12:05-13:45 ***Lunch***

13:45-14:40 **DEBATE I: Is there still a role for combined modality therapy for early stage cHL?**
Chair: Marc André (Namur, Yvoir)

13:45-13:50 Introduction

Audience votes "pro" or "con"

13:50 -14:05 Pro — Joachim Yahalom (New York)

14:05-14:20 Con — Peter Johnson (Southampton)

Audience votes again "pro" or "con"

14:20-14:40 Discussion

14:40-15:40 **SATELLITE SYMPOSIUM**
New insights in WM & MCL treatment landscape
Chairs: Gilles Salles (New York), Jorge J. Castillo (Boston)
Speakers: Olivier Tournilhac (Clermont-Ferrand), Martin H. Dreyling (Munich), Jorge J. Castillo (Boston)

This educational symposium is organized and funded by Beigene

15:45-17:40 **SESSION II – T-Cell Lymphoma**
Chairs: Catherine Thieblemont (Paris) and Pier Luigi Zinzani (Bologna)

15:45-15:50 Introduction

15:50-16:10 Peripheral T-cell lymphomas: diagnosis and refinement through understanding — Philippe Gaulard (Créteil)

16:10-16:30 First line treatment — Owen O'Connor (New York)

16:30-16:50 Salvage treatment — Pier Luigi Zinzani (Bologna)

16:50-17:10 How clinical trials and the latest update of the WHO classification are shaping current and future therapies for T-cell lymphoma including the use of stem cell transplant – Towards more subtype-specific approaches? — Francesco d'Amore (Aarhus)

17:10-17:40 *Discussion Q & A*

17:40-17:50 ***Coffee break***

17:50-18:55 **ROUNDTABLE I – Future directions in T-Cell Lymphoma**
Chair: Camille Laurent (Toulouse)

17:50-17:55 Introduction

17:55-18:15 Allogeneic stem cell transplantation for PTCL patients: Why and when? — Ghandi Laurent Damaj (Caen)

18:15-18:35 Perspectives of integrating immunotherapy in PTCL treatment algorithms — Gerald Wulf (Göttingen)

18:35-18:55 Discussion Q & A

18:55-19:55 **5 Simultaneous Meet the Expert sessions:**

1. Circulating free DNA — Davide Rossi (Bellinzona), Simone Ferrero (Turin)
2. Pet scan in lymphoma — Michel Meignan (Créteil) and Stefano Luminari (Modena)
3. Artificial intelligence for the diagnosis on lymphoma — Camille Laurent (Toulouse) and Ahmet Dogan (New York)
4. Follicular lymphoma — Christian Buske (Ulm) and Nathan Fowler (Houston)
5. Car T-cell — Stephen Schuster (Philadelphia) and Catherine Thieblemont (Paris)

Saturday, November 7

11:00-12:55 **SESSION III – Follicular Lymphoma**
Chairs: Christian Buske (Ulm) and Franck Morschhauser (Lille)

11:00-11:05 *Introduction*

11:05-11:25 Diagnostics — Wolfram Klapper (Kiel)

11:25-11:45 First line — Stefano Luminari (Modena)

11:45-12:05 Salvage treatment — Franck Morschhauser (Lille)

12:05-12:25 Challenges in FL – POD24 — Emmanuel Bachy (Lyon)

12:25-12:30 *EZH2 gain-of-function mutations are not associated with more favorable prognosis in relapsed/refractory follicular lymphoma: a preliminary analysis on 908 patients* — *Csaba Bödör (Budapest)*

12:30-12:55 *Discussion Q & A*

12:55-14:30 ***Lunch***

13:30-14:30 **SATELLITE SYMPOSIUM**
Immunotherapy: the new cornerstone of lymphoma care
Chair: Stefano Luminari (Reggio Emilia)
Speakers: Stefano Luminari (Reggio Emilia), Andrew Davies (Southampton) and Marc André (Namur)

This educational symposium is organized and funded by Celgene | A Bristol Myers Squibb Company

14:35-15:35 **Mentored Poster Walk**
Leader: Elias Campo (Barcelona)

15:35-16:30 **DEBATE II: Can we avoid chemotherapy in the management of Follicular Lymphoma?**
Chair: Gilles Salles (New York)

15:35-15:40 *Introduction*

Audience votes "yes" or "no"

15:40-15:55 In defense of the position «Yes» — Nathan Fowler (Houston)

15:55-16:10 In defense of the position «No» — Umberto Vitolo (Turin)

Audience votes "yes" or "no"

16:10-16:30 *Discussion*

16:30-16:40 ***Coffee break***

16:40-18:15 **SESSION IV – Rare Lymphomas – Marginal Zone Lymphoma and Waldenström Macroglobulinemia**
Chairs: Catherine Thieblemont (Paris) and Christian Buske (Ulm)

16:40-16:45 *Introduction*

16:45-17:05 Diagnostics — Maurilio Ponzoni (Milan)

17:05-17:25 Waldenström macroglobulinemia — Jorge J. Castillo (Boston)

17:25-17:45 Marginal Zone Lymphoma — Emanuele Zucca (Bellinzona)

17:45-17:50 *Macroglobulinemia Waldenström– a single centre experience* — *Cátia Sol Reis (Porto)*

17:50-18:15 *Discussion Q & A*

18:15-19:20 **ROUNDTABLE II – Where to go in rare B-Cell Lymphomas**
Chair: Markus Raderer (Vienna)

18:15-18:20 *Introduction*

18:20-18:40 Marginal Zone Lymphoma - case reports — Alexander Grunenberg (Ulm)

18:40-19:00 What we can learn from a single case of ENMZL with Multiple Mucosal Sites presentation? — Izidore S. Lossos (Miami)

19:00-19:20 *Discussion*

Sunday, November 8

09:30-11:25 **SESSION V – Mantle Cell Lymphoma**
Chairs: Olivier Hermine (Paris) and Elias Campo (Barcelona)

09:30-09:35 *Introduction*

09:35-09:55	Diagnostics	Elias Campo (Barcelona)
09:55-10:15	First line treatment	Steven Le Gouill (Nantes)
10:15-10:35	Salvage treatment	Martin H. Dreyling (Munich)
10:35-10:55	BTK failures	Olivier Hermine (Paris)
10:55-11:00	*TP53 status in Mantle Cell Lymphoma (MCL) - a 10-year single center experience*	*Ezzat Elhassadi (Waterford)*
11:00-11:25	*Discussion Q & A*	
11:25-13:05	***Lunch***	
13:05-15:00	**SESSION VI – Diffuse Large B-Cell Lymphoma** **Chairs: Catherine Thieblemont (Paris) and Davide Rossi (Bellinzona)**	
13:05-13:10	*Introduction*	
13:10-13:30	Diagnostics	Thierry Molina (Paris)
13:30-13:50	First line	Andy Davies (Southampton)
13:50-14:10	Relapse	Jason Westin (Houston)
14:10-14:30	CAR – T cells	Stephen Schuster (Philadelphia)
14:30-14:35	*Improved personalized survival prediction of patients with diffuse large b-cell lymphoma using gene expression profiling*	*Miguel Cid López (Santiago de Compostela)*
14:35-15:00	*Discussion Q & A*	
15:00-15:45	**Key Note Lecture: Biology and New Targets in DLBCL**	Riccardo Dalla Favera (New York)
15:45-15:50	*Discussion*	

15:50-16:50	**SATELLITE SYMPOSIUM** **How I treat relapsed/refractory disease – DLBCL and CLL** **Chair:** Gilles Salles (New York) **Speakers:** Marie-Jose Kersten (Amsterdam), Kieron Dunleavy (Washington), Francesc Bosch (Barcelona), Astrid Pavlosky (Buenos Aires) *This educational symposium is organized and funded by the Lymphoma Hub*

16:55-17:50	**DEBATE III: Do we still need ASCT in MCL?** **Chair: Olivier Hermine (Paris)**

16:55-17:00 *Introduction*

Audience votes "pro" or "con"

17:00-17:15 Pro — Marco Ladetto (Alessandria)

17:15 -17:30 Con — Georg Hess (Mainz)

Audience votes "pro" or "con"

17:30-17:50 *Discussion*

17:50-18:00 ***Coffee break***

18:00-19:35 **SESSION VII – Novel Therapeutic Concepts in B-Cell Lymphomas**
Chair: Corinne Haioun (Créteil)

18:00-18:05 *Introduction*

18:05-18:25 Genetics-driven epigenetic dysregulation in lymphoma: therapeutic implications — Laura Pasqualucci (New York)

18:25-18:45 Next generation CAR-T cells — Renier Brentjens (New York)

18:45-19:05 Checkpoint Inhibitors and bispecific antibodies — Stephen Ansell (Rochester)

19:05-19:10 *Bone marrow microenvironment lymphocytes measured by flow cytometry can predict early relapse in diffuse large B cell lymphoma patients* — *Laura Korin (Buenos Aires)*

19:10-19:35 *Discussion Q & A*

19:35-19:40 ***Closing Remarks***

MEETING CLOSURE